QL1706 As Second-line Treatment in Patients with Advanced Hepatocellular Carcinoma

PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 1, 2025

Primary Completion Date

August 1, 2026

Study Completion Date

August 1, 2026

Conditions

HCC - Hepatocellular Carcinoma

Interventions

DRUG

QL1706

Drug: QL1706 7.5 mg/kg administered as IV infusion on Day 1 of each 21-day cycle

Trial Locations (1)

Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China, Wuhan

All Listed Sponsors

collaborator

Qilu Pharmaceutical Co., Ltd.

INDUSTRY

lead

Wan-Guang Zhang

OTHER